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Background: Long-term nocturnal non-invasive mechanical ventilation (NIMV) is an
effective treatment for obesity-hypoventilation syndrome (OHS), improving central carbon
dioxide (CO2) sensitivity. Leptin might contribute to sustain adequate ventilation in
obesity. The aim of the study was to investigate the role of leptin in the OHS pathogenesis
looking at its relationship to CO2 sensitivity before and after NIMV in OHS patients.
Methods: In six obese patients (3F/3M; aged 6379 yr; BMI 47.074.5 kg/m2) with OHS and
without obstructive sleep apnoea–hypopnoea (OSAH) diurnal arterial blood gases, fasting
plasma leptin concentration and CO2 chemosensitivity were determined before and after
10.375.6 (range 6–20) months of NIMV.
Results: After NIMV improvements were observed in gas exchange (PaO2 from 51.376.7 to
75.0710.3mmHg, po0.01; PaCO2 from 55.574.8 to 43.771.2mmHg, po0.01; [HCO3]
from 33.373.8 to 29.871.7mmol/l, po0.05) and CO2 chemosensitivity, measured as P0.1/
PetCO2 slope (from 0.0970.07 to 0.1870.07 cmH2O/mmHg, po0.05) and VE/PetCO2 slope
(from 0.470.3 to 0.970.5 l/min/mmHg, p ¼ 0:07). Plasma leptin increased from
34.5721.1 ng/ml to 50.2722.9 ng/ml (po0.01) after NIMV and changes of the P0.1/
PetCO2 slope correlated with percent changes of plasma leptin (r2 ¼ 0:79, po0.05).
Conclusions: These findings suggest a possible role of leptin in the recovery of
neuromuscular response to hypercapnia obtained during long-term nocturnal NIMV in
OHS patients without OSAH.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Obesity-hypoventilation syndrome (OHS) is commonly de-
fined as a combination of obesity and awake arterial
hypercapnia in the absence of other known causes of
chronic alveolar hypoventilation1. A reduced electromyo-
graphic, neuromuscular and ventilatory response to hyper-
capnia is observed in patients with OHS2 and long-term
application of non-invasive mechanical ventilation (NIMV)
during sleep in these patients is able to improve awake
arterial blood gases3,4 by partially restoring central CO2
chemosensitivity.5
Studies in animals suggest that modulation of the central
chemoreflex by leptin may be implicated. In leptin deficient
mice (ob-ob), a genetic animal model of obesity, depressed
chemosensitivity and CO2 retention were reported particu-
larly during sleep.6,7 Leptin replacement studies in ob-ob
mice indicate that leptin works as stimulant on respiratory
centres, thus increasing ventilatory response to hypercap-
nia.7,8 It was postulated that leptin deficiency and/or
resistance can play a role in the pathogenesis of disorders
with abnormal control of breathing such as OHS.9
Therefore, we performed a pilot study aimed to investi-
gate the leptin role in the OHS pathogenesis. More
specifically, we tested the hypothesis that relatively low
plasma levels of leptin may contribute to explain the
blunted responsiveness to CO2 in obese patients with OHS
who do not have obstructive sleep apnoea–hypopnoea
(OSAH). The second aim was to clarify the mechanism
underlying the effectiveness of NIMV in the OHS treatment
in the absence of OSAH. We suspected that NIMV could
enhance the hypercapnic responsiveness by increasing the
leptin plasma levels.Patients and methods
We evaluated between September 2003 and December 2005
all patients with sleep disordered breathing at the Respira-
tory Medicine Unit of the Spedali Civili of Brescia. Eligible
patients were those with obesity (BMI430 kg/m2) and awake
arterial hypercapnia (PaCO2445mmHg), in the absence of
other known causes of chronic alveolar hypoventilation, in a
stable condition and naive to NIMV treatment. Thyroid
function was checked to exclude hypothyroidism. All the
women were in menopausal status and none was taking
replacement hormone therapy. No patients assumed new
drugs during the study period. Pulmonary function testing,
including determination of lung volumes, was performed to
eliminate subjects with obstructive and restrictive ventila-
tory dysfunctions. Maximal inspiratory and expiratory
pressures were measured to document normal respiratory
muscles function. We excluded from the study patients with
concomitant OSAH syndrome, defined as an obstructive
apnoea–hypopnoea index (AHI)X5, calculated by including
only the obstructive respiratory events in tracings obtained
during an overnight cardiorespiratory polysomnography
performed by an Embletta pds recorder (Flagahf Reykjavı´ck,
Iceland).
Patients were treated with non-invasive pressure support
ventilation with BiPAP (BiPAP Synchrony, Respironics) via
nasal mask. The expiratory positive airway pressure (EPAP)was set at 4 cm H2O in all patients to avoid CO2 rebreathing,
and the inspiratory positive airway pressure (IPAP) was
increased until the nocturnal oxygen saturation of haemo-
globin in arterial blood (SaO2) was490% or the maximum
tolerance of the patients was attained. If the IPAP was not
sufficient to maintain nocturnal SaO2 490%, oxygen was
added to the ventilatory circuit. During the follow-up
periodically the patients were interviewed to assess their
compliance with the treatment, arterial blood gases analysis
was performed and an overnight cardiorespiratory poly-
somnography was repeated. When the awake arterial carbon
dioxide tension (PaCO2) was o45mmHg, the NIMV treat-
ment was considered as effective.
In baseline conditions diurnal arterial blood gases analysis
and plasma leptin determination (Radioimmunoassay, DRG
Instruments GmbH, Germany; assay reproducibility: 75%;
accuracy: 70.5 ng/ml) were performed at 8:00 in the
morning while fasting. In the same circumstances the values
of plasma leptin were obtained from six eucapnic (three
male, three female) obese subjects without OSAH (AHIo5)
and OHS on sleep studies. They were selected among the
obese subjects referred to our sleep laboratory on a one to
one basis matching for sex, age and BMI. Baseline measure-
ments of ventilatory parameters and P0.1 were performed
breathing room air and during progressive hypercapnic
stimulus, using the rebreathing technique described by
Read.10 The measurement of P0.1 was performed according
to the method described by Whitelaw et al.11 The central
sensitivity to hypercapnia was assessed as neuromuscular
and ventilatory response by the relationship between P0.1
and PetCO2 (P0.1/PetCO2 slope) and between minute
ventilation (VE) and PetCO2 (VE/PetCO2 slope), respectively.
When the effectiveness of the NIMV was achieved,
baseline measurements were repeated using the same
techniques.
Statistical analysis
Data are expressed as mean7standard deviation (SD). Pre-
and post-NIMV variables were compared by using a paired t-
test, after checking the normality and homoscedasticity of
the data sets. Analysis of variance (ANOVA) was carried out
among leptin plasma levels of the OHS patients before and
after NIMV and of the eucapnic obese subjects, and, if
significant, paired and unpaired t-tests were used as post-
hoc test. Differences were considered as significant when
the probability of type I error was o5%. If significant post-
NIMV changes were detected, correlations were performed
using the Spearman’s rank-order test.
Results
Anthropometric characteristics, plasma leptin concentra-
tion, diurnal arterial blood gases and control of breathing
parameters of six OHS patients before and after 10.3+5.6
(range 6–20) months of nocturnal NIMV and of six eucapnic
obese subjects without OSAH are shown in Table 1. The IPAP
established at the end of the in-hospital NIMV adaptation
period was 12.371.2 cmH2O. In OHS patients, after noctur-
nal NIMV, the leptin plasma levels increased significantly, but
they were still lower than the leptin levels of the eucapnic
ARTICLE IN PRESS
Table 1 Anthropometric characteristics, plasma leptin concentration, diurnal arterial blood gases and control of breathing
parameters in OHS patients, before (OHS) and after NIMV (OHS post-NIMV), and of six eucapnic obese subjects (OB eucapnic).
OHS OHS post-NIMV OB eucapnic
Age (yr) 6379 — 6574
Sex (male/female) 3/3 — 3/3
BMI (kg/m2) 4775 4575 4472
Plasma leptin (ng/ml) 35721 50723# 88728#**
PaO2 (mmHg) 51.376.7 75.0710.3
# 91.772.9#**
PaCO2 (mmHg) 55.574.8 43.771.2
# 41.571.0#**
[HCO3
] (mmol/l) 33.373.8 29.871.7* 26.371.6#**
pH 7.4170.03 7.4270.02 7.4170.01
Resting VE (l/min) 14.374.6 17.372.6 —
Resting P0.1 (cmH2O) 3.271.1 3.171.1 —
P0.1/PetCO2 slope (cmH2O/mmHg) 0.0970.07 0.1870.07
* —
VE/PetCO2 slope (l/min/mmHg) 0.470.3 0.970.5y —
PetCO2 threshold (mmHg) 59.778.5 50.074.3
* —
BMI: body mass index; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; [HCO3
]: arterial bicarbonate
concentration; VE: minute ventilation; P0.1: occlusion pressure; P0.1/PetCO2 slope: slope of the relationship between P0.1 and PetCO2
during rebreathing; VE/PetCO2 slope: slope of the relationship between VE and PetCO2 during rebreathing; PetCO2 threshold: PetCO2 of
the point of intersection of the line drawn through the basal P0.1 and the P0.1/PetCO2 slope. Data are mean7SD;
#po0.01 vs OHS;
**po0.01 vs OHS post-NIMV; *po0.05 vs OHS; yp ¼ 0:07 vs OHS.
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Figure 1 Individual values (: female; m: male) and means
(bars) of plasma leptin levels of the OHS patients, before (OHS)
and after NIMV (OHS post-NIMV), and of six eucapnic obese
subjects (OB eucapnic). None of the subjects suffered from
OSAH. #po0.01 vs OHS; ypo0.01 vs OHS post-NIMV.
NIMV in obesity-hypoventilation syndrome 1193obese subjects (Fig. 1). In OHS patients the diurnal arterial
blood gases improved significantly after NIMV. Although
resting VE increased after NIMV, the changes of diurnal VE
and P0.1 were not significant. After NIMV the P0.1/PetCO2
slope increased significantly, although it was still lower than
the normal values of our lab (0.3–0.6 cmH2O/mmHg), the
VE/PetCO2 slope also increased, but not significantly
(p ¼ 0:07), and the PetCO2 threshold decreased significantly
(Fig. 2).
Changes of leptin plasma levels, expressed as percentage
of baseline, correlated positively with changes of P0.1/
PetCO2 slope (r2 ¼ 0:79, po0.05) (Fig. 3).Discussion
The most important findings of this study are the following:
(i) leptin plasma levels are lower in OHS patients without
OSAH than in matched eucapnic obese subjects without
OSAH; (ii) the OHS patients without OSAH who achieve
normal diurnal arterial blood gases following NIMV show an
increase in leptin plasma levels that correlates with the
degree of improvement of neuromuscular response to
hypercapnia, as expressed by the P0.1/PetCO2 slope.
In this pilot study the relationships between changes in
leptin plasma levels and effects on control of breathing of
prolonged ventilatory support were assessed in a small group
of OHS patients without OSAH and clearly its significance
needs to be further investigated in larger groups of such
patients. It must be recognized, however, that this is the
greatest cohort of OHS patients without OSAH followed
during long-term treatment with BiPAP in which these
measurements have been obtained.
We found that leptin plasma levels are elevated in obese
patients with OHS (normal range of our lab: 6–20 ng/ml for
healthy subjects with BMI between 19 and 24 kg/m2),
further increasing after effective treatment with NIMV.
However, their leptin plasma levels were below the values of
eucapnic healthy obese subjects with similar age, sex and
BMI (Fig. 1). Our findings suggest that OHS may be
determined, at least in part, by not sufficiently high leptin
plasma levels. Phipps et al. previously reported augmented
leptin plasma levels in hypercapnic obese subjects as
compared to eucapnic obese subjects,12 but they did not
measure hypercapnic ventilatory response and all the
patients had severe OSAH, a possible confounding factor.
Again, a recent study performed in a group of 14
hypercapnic obese subjects with OSAH ðRDI ¼ 44 35Þ,
showed a significant reduction of leptin plasma levels in
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Figure 2 Individual values (: female; m: male) of P0.1/PetCO2 slope, VE/PetCO2 slope and PetCO2 threshold in the OHS patients
before (OHS) and after NIMV (OHS post-NIMV). **po0.05; yp ¼ 0:07.
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Figure 3 Relationship between leptin changes (% of baseline)
and changes in the P0.1/PetCO2 slope. : female; m: male.
S. Redolfi et al.1194nine of them ðRDI ¼ 53 35Þ after NIMV (six were treated
with continuous positive airway pressure (CPAP) and only
three with BiPAP). Such reduction in leptin plasma levels did
not occur in the other five subjects who refused NIMV.13
Indeed, several previous studies have reported higher leptin
plasma levels in patients with OSAH than in controls14–17 and
a significant reduction in leptin plasma levels after the
treatment with nasal CPAP.14,16,18,19 Conversely, other
authors found that leptin plasma levels in obese patients
with OSAH were not different from obese control sub-
jects20,21 and that leptin plasma levels did not decrease with
CPAP therapy.21 Because of these conflicting results we
decided to exclude OSAH patients from the study.
Another potential confounding factor is represented by
the variation of BMI during the follow-up period. The weight
loss has been shown to significantly increase centralsensitivity to hypercapnia in OHS patients, as measured by
the electromyographic response of the diaphragm,22 with
consequent disappearance of respiratory failure.23 More-
over, changes in body weight are associated with changes in
leptin plasma levels, which decrease more than 50% with a
weight loss of 10%.24 The increase in central sensitivity to
hypercapnia and in leptin plasma levels observed in our
patients cannot be ascribed to variations of BMI that was
essentially unchanged after NIMV.
The results of our study confirm that long-term nocturnal
NIMV improves arterial blood gases in the OHS patients,
partly by restoring the sensitivity of the respiratory centres,
as previously shown in other studies.4,5
Baseline P0,1 was elevated and similar to that reported by
De Lucas-Ramos et al.5 After NIMV diurnal resting VE and P0,1
did not change significantly, although VE was slightly
increased (Table 1).
On the other hand, the response of respiratory centres to
hypercapnia, expressed as P0.1/PetCO2 slope, increased
significantly after NIMV, although it did not reach the normal
range. The values both of P0.1/PetCO2 slope and of VE/
PetCO2 slope, before and after NIMV, were similar to those
reported by De Lucas-Ramos,5 but in our study the increase
of VE/PetCO2 slope was not significant ðp ¼ 0:07Þ probably
because of the smaller number of patients. Hence, it is
conceivable that the prolonged nocturnal ventilatory sup-
port and the increased CO2 chemosensitivity can sustain the
daytime PaCO2 decrease showed by our subjects, even in the
absence of diurnal significant increase in VE.
The novelty of the study is that the improvement of
sensitivity to hypercapnia in the OHS patients, following the
NIMV application, is associated with and could be partly due
to an increase in plasma levels of leptin, acting as
respiratory stimulant. Although we did not investigate the
mechanisms underlying the leptin increase during NIMV,
some hypothesis seem reasonable. First, it can be envisaged
that the increased production of leptin by adipose cells in
obese subjects might be impaired in the presence of chronic
hypoxia, decreasing its stimulant effect on respiratory
centres. Although there are no available data regarding
the effect of chronic hypoxia on leptin plasma levels,
prolonged hypoxia (2–3 weeks at high altitude) has been
ARTICLE IN PRESS
NIMV in obesity-hypoventilation syndrome 1195found to not modify or even reduce the leptin plasma levels
in non-obese healthy subjects.25,26 NIMV, through the
correction of chronic hypoxemia, could act on adipose cells
to restore the leptin production.
Second, since in non-obese healthy volunteers sleep
deprivation was associated with reduction in leptin plasma
levels27,28 and decreased hypercapnic ventilatory re-
sponse,29,30 NIMV might cause an elevation in leptin plasma
levels possibly by increasing the duration and quality
of sleep.
In conclusion, relatively low plasma levels of leptin could
play a role in the pathogenesis of OHS. In OHS patients
without OSAH the increased CO2 sensitivity occurring during
long-term NIMV is associated with and may be sustained by
the increment of leptin plasma levels that might contribute
to the effectiveness of this treatment in addition to the
simple ventilatory assistance.
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